57-41-0 | Phenytoin

Chemical type

• Antiseizure medication (ASM) and P-gp substrate

^[1]

• Aromatic antiepileptic drug

^[2]

Key properties

• Extruded from brain by P-gp, leading to lower brain concentrations in drug-resistant models
• Brain levels enhanced by P-gp inhibitors like tariquidar

^[1]

• Aromatic structure shared with other anticonvulsants like carbamazepine and phenobarbital; increases risk of hypersensitivity reactions including SJS/TEN; associated with type IV hypersensitivity response involving T-cell activation, cytokine release, and epidermal necrosis; genetic factors like HLA-B*15:02 allele predispose certain populations

^[2]

• Treatment of epilepsy (e.g., in drug-resistant temporal lobe epilepsy)
• Studied in rodent models for antiseizure efficacy with P-gp inhibition

^[1]

• Treatment of epilepsy, seizure disorders, cardiac arrhythmias, and trigeminal neuralgia; initiated for simple partial seizures in this case

^[2]

Classification by use

• Chemicals used as antiseizure medications
• P-gp substrates in epilepsy research

^[1]

• Anticonvulsants with known hypersensitivity potential
• Drugs for neurological disorders

^[2]

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

1. [Cite:1] Tolerability of tariquidar – A third generation P-gp inhibitor as add-on medication to antiseizure medications in drug-resistant epilepsy, Seizure: European Journal of Epilepsy, Volume 119, July 2024, Pages 44-51
2. [Cite:2] Stevens-Johnson syndrome triggered by phenytoin in a patient with type 2 diabetes and seizures, Exploratory Research in Clinical and Social Pharmacy, Volume 19, September 2025, 100624